Systemic Anti-Cancer Therapy Regimen Library
Neuroendocrine tumour Advanced - octreotide modified release
Treatment Overview
Dose and dosing frequency of octreotide modified release injection should be individualised.
- Typical starting doses are 20 mg to 30 mg 4 weekly.
- Doses may range from 10 mg to a maximum dose of 60 mg given at 2 to 4 weekly intervals depending on response.
- Use the regimen below of the appropriate dose for the patient.
Typical starting dose.
Typical starting dose.
Every 3 weeks is a non-standard frequency of administration.
Every 3 weeks is a non-standard frequency of administration.
Every 3 weeks is a non-standard frequency of administration.
Every 3 weeks is a non-standard frequency of administration.
Every 2 weeks is a non-standard frequency of administration.
Every 2 weeks is a non-standard frequency of administration.
Every 2 weeks is a non-standard frequency of administration.
Supportive Care Factors
No supportive care factors specified
References
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.